Log in to search using one of your social media accounts:

 

Novartis and The Max Foundation to provide cancer access programme in lower-income countries
Novartis has entered a new collaboration with The Max Foundation to support continued access to treatment free of charge for almost 34,000 patients suffering from chronic myeloid leukaemia (CML), gastrointestinal tumours (GIST) and other rare cancers … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 25, 2017 Category: Pharmaceuticals Source Type: news

Prostaglandin EI inhibits leukemia stem cells
(University of Iowa Health Care) Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2017 Category: Cancer & Oncology Source Type: news

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP), (Source: World Pharma News)
Source: World Pharma News - September 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Nigeria: Leukemia Patients Celebrate 10th World CML Day
[This Day] As patients of Chronic Myeloid Leukemia (CML) worldwide celebrate the 10th World CML Day today to raise awareness on a rare haematological disease that represents 15 to 20 per cent of all leukemia in adults and the needs of patients, a non-governmental organisation, Together Maxcare Foundation Nigeria, is pushing for more sensitivity to the plight of patients who have this rare type of leukemia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 22, 2017 Category: African Health Source Type: news

Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease
The tyrosine kinase inhibitor bosutinib, approved for chronic myeloid leukemia, reduced kidney growth rate in patients with autosomal dominant polycystic kidney disease (ADPKD) in a phase 2 study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 31, 2017 Category: Intensive Care Tags: Nephrology News Source Type: news

EMA accepts Pfizer ’s bosulif Type II Variation application for Ph+ CML
The European Medicines Agency (EMA) has approved for review a Type II Variation application for the use of Pfizer ’s bosulif (bosutinib) to treat patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

CML Blast Phase Outcomes Remain Poor in TKI Era, Prognostic Factors Identified
Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

CML Patients Approach Normal Life Expectancy With Imatinib Treatment
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study. (Source: CancerNetwork)
Source: CancerNetwork - July 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

FDA Grants Priority Review for New Leukemia Option
The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug ’s developer. (Source: CancerNetwork)
Source: CancerNetwork - July 20, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Pediatric Cancers Source Type: news

New approach to leukaemia can help improve successful treatment
(University of Liverpool) New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukaemia (CML) can safely increase treatment success and reduce negative side effects. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 12, 2017 Category: Biology Source Type: news

New approach to leukemia can help improve successful treatment
(University of Liverpool) New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2017 Category: Cancer & Oncology Source Type: news

Treatment-Free Remission in CML Sustainable After Nilotinib
Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks. (Source: CancerNetwork)
Source: CancerNetwork - July 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia & Lymphoma News Source Type: news

Dasatinib in Children: An Effective Alternative to Imatinib Dasatinib in Children: An Effective Alternative to Imatinib
In children and adolescents with chronic-phase chronic myeloid leukemia, dasatinib shows response rates and safety similar to those seen in adults.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

TKI De-escalation Safe in Most CML Patients With Major Molecular Response
A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2017 Category: Cancer & Oncology Tags: Chronic Myeloid Leukemia News Source Type: news

Dasatinib Is Safe, Effective in Pediatric Chronic Myeloid Leukemia
Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia News Pediatric Cancers Source Type: news

Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Jorge E. Cortes, MD Tags: Conferences/ASCO Hematology Chronic Myeloid Leukemia News Videos Hematologic Malignancies Source Type: news

Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: WebMD Health)
Source: WebMD Health - June 5, 2017 Category: Consumer Health News Source Type: news

Cancer Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 5, 2017 Category: Cancer & Oncology Tags: Oncology, Pediatrics, Pharmacy, News, Source Type: news

Cancer Drug, Dasatinib, Helps Some Kids With Rare Type of Leukemia
MONDAY, June 5, 2017 -- The cancer drug dasatinib shows promise in treating children with chronic myeloid leukemia (CML) caused by the gene BCR-ABL, also known as the Philadelphia chromosome, researchers report. " Despite the fact that there is a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2017 Category: General Medicine Source Type: news

Cancer Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news

Payments linked to higher odds of doctors prescribing certain cancer drugs
(UNC Lineberger Comprehensive Cancer Center) In preliminary findings (abstract 6510) that will be presented at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago on Saturday, June 3, researchers show that when physicians had to choose between multiple, on-patent drugs for metastatic kidney cancer and chronic myeloid leukemia, they were more likely to prescribe drugs from companies they had received general payments from. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2017 Category: International Medicine & Public Health Source Type: news

TKI Discontinuation Possible for Some CML Patients
Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2017 Category: Cancer & Oncology Authors: Ehab Atallah, MD Tags: Conferences/ASCO Hematology Chronic Myeloid Leukemia & Lymphoma Source Type: news

Cytogenetic Abnormalities Do Not Affect Prognosis in Pediatric CML
Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 22, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news

Kenya: Kenyan Study Shines New Light On Chronic Myeloid Leukaemia
[The Conversation Africa] Chronic myeloid leukaemia is a type of bone marrow cancer that goes on to affect the blood, then other organs and tissues. Previous research has linked it to exposure to high doses of radiation. The Conversation Africa's Health Editor Joy Wanja Muraya asked a team of Kenyan experts to explain their research into what other factors might predispose people to this type of cancer. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 22, 2017 Category: African Health Source Type: news

Insurance Status Influences Chronic Myeloid Leukemia Survival Outcomes
Insurance status at the time of chronic myeloid leukemia diagnosis appears to have an influence on survival outcomes, with the uninsured and those on Medicaid having worse overall survival. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Challenges in Molecular Monitoring for CML Treatment Response
This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 2, 2017 Category: Cancer & Oncology Authors: Susan Branford, MD Tags: Chronic Myeloid Leukemia Videos Hematologic Malignancies Source Type: news

Ponatinib Extends Survival Over Transplant in Chronic Phase CML
Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation. (Source: CancerNetwork)
Source: CancerNetwork - April 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
Source: CancerNetwork - March 29, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

New England Journal of Medicine publishes long-term results of Gleevec ®
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. (Source: World Pharma News)
Source: World Pharma News - March 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Final Results of Landmark Imatinib Study in CML Show Long-Term Benefit
The final, long-term analysis of the landmark IRIS study showed that imatinib ’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there's no evidence of safety concerns linked to long-term use of the drug, researchers saySource: HealthDay Related MedlinePlus Page: Chronic Myeloid Leukemia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 8, 2017 Category: Consumer Health News Source Type: news

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
WEDNESDAY, March 8, 2017 -- The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment -- with no signs of additional safety risks, a new study finds. Gleevec -- known generically as imatinib -- was hailed as a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 8, 2017 Category: Journals (General) Source Type: news

Second-Generation TKIs Can Be Stopped in Many CML Patients
Cessation of second-generation TKIs yielded good treatment-free remission rates in patients with chronic myeloid leukemia who had sustained deep molecular responses. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news

Smoking Worsens Prognosis for Patients With CML
Smoking is linked to mortality and to disease progression among patients with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 24, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news

CD86 Expression Correlates With Relapse in CML Patients
CML patients who have high expression of the T-cell inhibitory receptor (CTLA-4)-ligand CD86 on plasmacytoid dendritic cells have a higher risk of relapsing after discontinuing therapy with a tyrosine kinase inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - January 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Adding Pioglitazone Could Improve Molecular Response in CML Patients
A small preliminary study showed that adding pioglitazone to imatinib therapy might have a favorable impact on residual disease in chronic myeloid leukemia, as measured by conversion to molecular response 4.5. (Source: CancerNetwork)
Source: CancerNetwork - January 5, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Natural Killer Cells Play Role in Ability of CML Patients to Discontinue TKIs
Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib. (Source: CancerNetwork)
Source: CancerNetwork - December 29, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Stopping Drug Therapy for CML: EURO-SKI Results Stopping Drug Therapy for CML: EURO-SKI Results
This is the largest cohort to date of patients with chronic myeloid leukemia followed after stopping treatment with tyrosine kinase inhibitors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

At 2 Years, No CML Found in Half of Patients Who Stopped TKI Therapy
Cessation of tyrosine kinase inhibitor therapy may be possible in chronic myeloid leukemia patients with deep molecular response, according to the results of the Euro-Ski trial. (Source: CancerNetwork)
Source: CancerNetwork - December 4, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASH 2016 News Source Type: news

Global Health: Summer Project Turns Into Leukemia Testing Breakthrough
What began as a student effort at a lab in Seattle produced a test for chronic myeloid leukemia that works with a few spots of dried blood on a paper card. (Source: NYT Health)
Source: NYT Health - November 28, 2016 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Tests (Medical) Drugs (Pharmaceuticals) Leukemia Third World and Developing Countries Novartis AG Africa Gleevec Source Type: news

Bosutinib Offers Long-Term Efficacy in CML Patients Who Failed TKI Therapy
According to a long-term follow-up analysis of a phase I/II trial, bosutinib provides durable responses and a favorable toxicity profile in patients with chronic phase CML who are resistant/intolerant to other tyrosine kinase inhibitors. (Source: CancerNetwork)
Source: CancerNetwork - November 23, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Money in Medicine: Brian Druker on why he gets money from Gilead, not Gleevec
Dr. Brian Druker ’s name is practically synonymous with Gleevec, which is about as close as you can get to a miracle drug. Yet Druker has never directly benefited from Gleevec, which has greatly expanded the life expectancy for those with chronic myeloid leukemia. Because he didn’t invent and patent the drug, h e receives no royalties. He did give a couple of talks about it for drug maker Novartis, but then called it quits on those sorts of gigs. “I decided it was not what I want to be doing,”… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 22, 2016 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

Money in Medicine: Brian Druker on why he gets money from Gilead, not Gleevec
Dr. Brian Druker ’s name is practically synonymous with Gleevec, which is about as close as you can get to a miracle drug. Yet Druker has never directly benefited from Gleevec, which has greatly expanded the life expectancy for those with chronic myeloid leukemia. Because he didn’t invent and patent the drug, h e receives no royalties. He did give a couple of talks about it for drug maker Novartis, but then called it quits on those sorts of gigs. “I decided it was not what I want to be doing,”… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 22, 2016 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

PR1 Peptide Vaccine May Aid Leukemia Remission PR1 Peptide Vaccine May Aid Leukemia Remission
PR1 peptide vaccine may benefit many patients with myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndrome, findings from an early clinical trial suggest.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 9, 2016 Category: Allergy & Immunology Tags: Public Health & Prevention News Source Type: news

Immune Cell Protein Expression Could Offer Predictive Biomarker in CML
Expression levels of CD62L and related immunologic markers are correlated with treatment responses and outcome in patients with CML, according to a new analysis. The markers could have prognostic value if validated in other cohorts. (Source: CancerNetwork)
Source: CancerNetwork - November 9, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Long-Term Follow-Up Shows Imatinib Discontinuation Remains Safe
The STIM1 study shows that patients with chronic myeloid leukemia who have undetectable minimal residual disease can safely discontinue imatinib therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news

High up-front costs could delay access to life-saving blood cancer drugs for Medicare patients
(UNC Lineberger Comprehensive Cancer Center) Researchers from the UNC Lineberger Comprehensive Cancer Center and collaborators report that nearly a third of a group of patients with chronic myeloid leukemia, and who have Medicare prescription drug insurance, did not start treatment within six months of diagnosis with any of three targeted drugs that have led to dramatic improvements in survival for the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2016 Category: Cancer & Oncology Source Type: news

Genetics Home Reference: chronic myeloid leukemia
https://ghr.nlm.nih.gov/condition/chronic-myeloid-leukemia (Source: NLM General Announcements)
Source: NLM General Announcements - September 28, 2016 Category: Databases & Libraries Source Type: news

Learning units launched to mark leukaemia day
Nursing Times has today launched new online education resources on haematological cancers known as myeloproliferative neoplasms to coincide with International Chronic Myeloid Leukaemia Day. (Source: Nursing Times)
Source: Nursing Times - September 22, 2016 Category: Nursing Source Type: news